Down-regulated FcγRII Expression on Plasma Cells is Associated with the Disease Activity of ANCA-associated Vasculitis

Chen Wang,Yan Gong,Ran You,Zhi-Ying Li,Ming-Hui Zhao,Min Chen
DOI: https://doi.org/10.1093/rheumatology/keac524
2022-01-01
Rheumatology
Abstract:OBJECTIVES:Inhibitory FcγRIIB/CD32B on B cells are critical for immunity regulation to help maintain peripheral tolerance. Altered FcγRIIB expression on B cells has been observed in several autoimmune diseases, and animal studies have suggested that FcγRIIB on B cells participates in the pathogenesis of ANCA-associated vasculitis (AAV). Here, we investigated the expression of FcγRII (FcγRIIB) on various B cell subsets and the correlation of FcγRII/CD32 expression with disease activity in AAV patients.MATERIAL AND METHODS:Blood samples of patients with AAV in active stage and in remission were collected. FcγRII/CD32 expressions on various B cell subsets of the whole blood were detected by flow cytometry, and their correlation with clinical and pathological data was analysed.RESULTS:The expression of FcγRII/CD32 on plasma cells was significantly lower in AAV patients in active stage than those in both AAV patients in remission and healthy donors. Furthermore, the expression of FcγRII/CD32 on plasma cells negatively correlated with BVAS and percentages of cellular crescents in renal biopsies.CONCLUSIONS:There is a down-regulation of FcγRIIB/CD32B expression on B cells in patients with AAV, which is associated with the disease activity of AAV.
What problem does this paper attempt to address?